145 related articles for article (PubMed ID: 1375115)
21. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for urogenital cancer. Urological rhG-CSF Study Group.
Aso Y; Akaza H
J Urol; 1992 Apr; 147(4):1060-4. PubMed ID: 1372661
[TBL] [Abstract][Full Text] [Related]
22. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia.
Gillan ER; Christensen RD; Suen Y; Ellis R; van de Ven C; Cairo MS
Blood; 1994 Sep; 84(5):1427-33. PubMed ID: 7520770
[TBL] [Abstract][Full Text] [Related]
23. Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.
Somlo G; Sniecinski I; Odom-Maryon T; Nowicki B; Chow W; Hamasaki V; Leong L; Margolin K; Morgan R; Raschko J; Shibata S; Tetef M; Molina A; Berenson RJ; Forman SJ; Doroshow JH
Blood; 1997 Mar; 89(5):1521-8. PubMed ID: 9057632
[TBL] [Abstract][Full Text] [Related]
24. Pulmonary absorption of recombinant methionyl human granulocyte colony stimulating factor (r-huG-CSF) after intratracheal instillation to the hamster.
Niven RW; Lott FD; Cribbs JM
Pharm Res; 1993 Nov; 10(11):1604-10. PubMed ID: 7507241
[TBL] [Abstract][Full Text] [Related]
25. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
Takano H; Sawada K; Sato N; Natoya A; Tarumi T; Hirayama S; Koizumi K; Takahashi TA; Sekiguchi S; Koike T
Leuk Lymphoma; 1996 May; 21(5-6):473-8. PubMed ID: 9172813
[TBL] [Abstract][Full Text] [Related]
26. Effect of continuous subcutaneous administration of a small dose of granulocyte colony stimulating factor (G-CSF) by the use of a portable infusion pump in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Furuya H; Wakayama T; Ohguni S; Yamauchi K; Tanaka J; Hatazoe T; Kato Y
Int J Hematol; 1995 Apr; 61(3):123-9. PubMed ID: 7541257
[TBL] [Abstract][Full Text] [Related]
27. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy.
Furman WL; Fairclough DL; Huhn RD; Pratt CB; Stute N; Petros WP; Evans WE; Bowman LC; Douglass EC; Santana VM
J Clin Oncol; 1991 Jun; 9(6):1022-8. PubMed ID: 2033415
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects.
Akizuki S; Mizorogi F; Inoue T; Sudo K; Ohnishi A
Bone Marrow Transplant; 2000 Nov; 26(9):939-46. PubMed ID: 11100272
[TBL] [Abstract][Full Text] [Related]
30. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
[TBL] [Abstract][Full Text] [Related]
31. Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy.
Furman WL; Rodman JH; Tonda ME; Luo X; Arnold B; Marina N; Garrison L; Hanna R; Pratt CB; Meyer WH
Cancer Chemother Pharmacol; 1998; 41(3):229-36. PubMed ID: 9443640
[TBL] [Abstract][Full Text] [Related]
32. Autologous transplantation with peripheral blood stem cells in children and young adults after myeloablative treatment: nonrandomized comparison between GM-CSF and G-CSF for mobilization.
Klingebiel T; Handgretinger R; Herter M; Eppinger T; Bader P; Lang P; Dopfer R; Scheel-Walter H; Haus U; Niethammer D
J Hematother; 1995 Aug; 4(4):307-14. PubMed ID: 7489145
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic studies of intravenous glycosylated recombinant human granulocyte colony-stimulating factor in various hematological disorders: inverse correlation between the half-life and bone marrow myeloid cell pool.
Watari K; Ozawa K; Takahashi S; Tojo A; Tani K; Kamachi S; Asano S
Int J Hematol; 1997 Jul; 66(1):57-67. PubMed ID: 9220661
[TBL] [Abstract][Full Text] [Related]
34. [Clinical evaluation of recombinant human G-CSF in children with cancer].
Tsukimoto I; Hanawa Y; Takaku F; Asano S; Ueda K; Tsuchida M; Sato T; Ohira M; Hoshi Y; Nishihira K
Rinsho Ketsueki; 1990 Oct; 31(10):1647-55. PubMed ID: 1701501
[TBL] [Abstract][Full Text] [Related]
35. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.
Ribas A; Albanell J; Bellmunt J; Solé-Calvo LA; Bermejo B; Gallardo E; Vidal R; Vera R; Eres N; Carulla J; Baselga J
J Clin Oncol; 1996 May; 14(5):1573-80. PubMed ID: 8622074
[TBL] [Abstract][Full Text] [Related]
36. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH
J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic and pharmacodynamic analysis of subcutaneous recombinant human granulocyte colony stimulating factor (lenograstim) administration.
Hayashi N; Kinoshita H; Yukawa E; Higuchi S
J Clin Pharmacol; 1999 Jun; 39(6):583-92. PubMed ID: 10354962
[TBL] [Abstract][Full Text] [Related]
38. Kinetics of serum granulocyte-colony stimulating factor (G-CSF) concentration and G-CSF receptor expression during G-CSF treatment of cyclophosphamide-treated mice.
Matsuzaki G; Li XY; Ohyama Y; Nomoto K
Int J Immunopharmacol; 1996; 18(6-7):363-9. PubMed ID: 9024937
[TBL] [Abstract][Full Text] [Related]
39. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial.
Wagner LM; Billups CA; Furman WL; Rao BN; Santana VM
J Clin Oncol; 2004 May; 22(10):1886-93. PubMed ID: 15143081
[TBL] [Abstract][Full Text] [Related]
40. Subcutaneous administration of recombinant human granulocyte colony-stimulating factor (KRN8601) in intensive chemotherapy for patients with advanced lung cancer.
Eguchi K; Shinkai T; Sasaki Y; Tamura T; Ohe Y; Nakagawa K; Fukuda M; Yamada K; Kojima A; Oshita F
Jpn J Cancer Res; 1990 Nov; 81(11):1168-74. PubMed ID: 1702415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
